Literature DB >> 20551275

Clonal relationship of extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue involving different sites.

Sergej Konoplev1, Pei Lin, Xiaoyan Qiu, L Jeffrey Medeiros, C Cameron Yin.   

Abstract

Patients with mucosa-associated lymphoid tissue (MALT) lymphoma often have multiple sites of disease at initial diagnosis or during the clinical course. The neoplasms at multiple sites are often presumed to be identical, indicating dissemination or relapse. However, evidence to support this presumption is usually not available. We compared IGH VDJ sequences in 4 patients with 2 sequential sites of MALT lymphoma. The specimen pairs were stomach and nasopharynx, stomach and lung, ocular adnexa and nasopharynx, and ocular adnexa and parotid gland. The median interval between biopsies was 4 months (range, 1-32 months). Monoclonal IGH gene rearrangement was detected in all cases. In 3 patients, the VDJ sequences were distinct; in 1 patient the 2 biopsy specimens shared the same clone. MALT lymphomas involving multiple sites in a patient are usually not clonally related but arise independently, likely due to chronic antigenic stimulation, inducing oligoclonal B-cell proliferations and eventually a dominant B-cell clone.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20551275     DOI: 10.1309/AJCP0HT6ZGSZKNFT

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

1.  Molecular and cytogenetic characterization of expanded B-cell clones from multiclonal versus monoclonal B-cell chronic lymphoproliferative disorders.

Authors:  Ana Henriques; Arancha Rodríguez-Caballero; Ignacio Criado; Anton W Langerak; Wendy G Nieto; Quentin Lécrevisse; Marcos González; Emília Cortesão; Artur Paiva; Julia Almeida; Alberto Orfao
Journal:  Haematologica       Date:  2014-01-31       Impact factor: 9.941

2.  Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study.

Authors:  Sung Yong Oh; Won Seog Kim; Jin Seok Kim; Seok Jin Kim; Suee Lee; Dae Ho Lee; Jong-Ho Won; In Gyu Hwang; Min Kyoung Kim; Soon Il Lee; Yee Soo Chae; Deok-Hwan Yang; Hye Jin Kang; Chul Won Choi; Jinny Park; Hyo Jung Kim; Jung Hye Kwon; Ho Sup Lee; Gyeong-Won Lee; Hyeon Seok Eom; Jae-Yong Kwak; Won Sik Lee; Cheolwon Suh; Hyo-Jin Kim
Journal:  Int J Hematol       Date:  2010-09-14       Impact factor: 2.490

3.  Stage IV intramucosal gastric marginal zone B cell lymphoma of mucosa-associated lymphoid tissue type.

Authors:  Masahiko Ohtaka; Tadashi Sato; Shouji Kobayashi; Ryouta Sueki; Tatsuya Yamaguchi; Tomoyoshi Uetake; Hiroyuki Ohtsuka; Noriaki Iwao; Keita Kirito; Nobuyuki Enomoto
Journal:  Clin J Gastroenterol       Date:  2013-03-20

Review 4.  Role of Helicobacter pylori in gastric mucosa-associated lymphoid tissue lymphomas.

Authors:  Marta-Isabel Pereira; José Augusto Medeiros
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

5.  Ocular adnexal non-Hodgkin's lymphoma: a review of epidemiology and risk factors.

Authors:  Roxana Moslehi; Maria J Schymura; Seema Nayak; F Bruce Coles
Journal:  Expert Rev Ophthalmol       Date:  2011-04

6.  Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the oromaxillofacial head and neck region: A retrospective analysis of 105 patients.

Authors:  Tian Zhang; Yunteng Wu; Houyu Ju; Jian Meng; Wei Guo; Guoxin Ren
Journal:  Cancer Med       Date:  2019-11-15       Impact factor: 4.452

Review 7.  Concurrent gastric and pulmonary mucosa-associated lymphoid tissue lymphomas with pre-existing intrinsic chronic inflammation: a case report and a review of the literature.

Authors:  Soo-Yeon Oh; Na-Young Kim; Dong Hyun Oh; Soo Mee Bang; Yoon Jin Choi; Ju Yub Lee; Kyung Won Lee; Ho Il Yoon; Hee Chul Yang; Jin Ho Paik; Dong Ho Lee; Hyun Chae Jung
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.